Understanding Clinical Variances in Urinary Isolates: Pathogenic vs. Non-Pathogenic Impacts in Tertiary Healthcare of North India

INTRODUCTIONThe clinical decision-making landscape in urinary tract infections (UTIs) hinges on discerning between pathogenic and non-pathogenic organisms. The accurate interpretation of culture results relies significantly on precise collection methods, the patients clinical status, and organism characteristics. This pioneering study, the first of its kind, systematically examines the clinical outcomes associated with pathogenic and non-pathogenic urinary isolates. Nestled within the tertiary healthcare context, this research not only fills a critical knowledge gap but also endeavors to unravel the economic and clinical implications that underscore the distinctive nature of UTIs in North India. OBJECTIVETo conduct a comprehensive assessment of the clinical and economic impacts of urinary tract infections (UTIs) caused by pathogenic and non-pathogenic organisms in North Indias tertiary healthcare. Evaluate hospitalization duration, antimicrobial usage, costs, mortality rates, and patient demographics to inform customized management strategies, optimize resource allocation, and enhance overall UTI patient care. METHODOLOGYConducted at AIIMS Rishikesh, a longitudinal-exploratory study over 18 months included 275 participants meeting specific criteria. Data entry via Redcap ensured precision. SPSS (Version 23) facilitated statistical analysis encompassing chi-square tests and logistic regression, prioritizing ethical considerations and patient consent. RESULTSPathogenic Cases: Comprising 90.54% of the cohort, average hospital stays of 14.68 days, and expenses of $29.12 on antibiotics with a mortality rate of 3.6%. Pathogenic-Commensal Cases: Constituting 61.81% with an average stay of 13.88 days, antibiotic expenses at $28.46{+/-}9.33, and a mortality rate of 3.2%. Pathogenic Colonizer Cases: Accounting for 14.18%, with an average stay of 14.67 days, antibiotic expenses at $27.69{+/-}11.02, and a mortality rate of 0.36%. Direct Pathogenic Cases: Representing 14.54% with longer stays (18.08 days) and higher antibiotic expenses $33.28{+/-}5.01 Non-Pathogenic Cases: Makeup 9.45% with variable stays and expenses. DISCUSSIONThis ground-breaking study explores clinical variances in urinary isolates, distinguishing pathogenic (90.54%) and non-pathogenic cases (9.45%). Subtypes within pathogenic cases offer nuanced insights, guiding tailored patient care and optimizing resources. Non-pathogenic cases, though fewer, reveal variability, emphasizing the studys depth. Recognizing the clinical impact of seemingly benign isolates becomes crucial amid rising antimicrobial resistance, urging judicious antimicrobial prescription. CONCLUSIONThis study pioneers insights into North Indias urinary isolates, emphasizing customized management. Distinguishing pathogenic from non- pathogenic cases, especially subtypes, is imperative. Identifying and avoiding unnecessary antimicrobial use emerge as pivotal interventions, contributing significantly to global antimicrobial resistance efforts and alleviating economic burdens on healthcare systems worldwide.